Evidence map›Paper›PMID 40181101›Full record

ArticleScientific reports2025

Peptides developed against receptor binding sites of the E glycoprotein neutralize tick-borne encephalitis virus.

Patrícia Petroušková, Katarína Bhide, Evelína Mochnáčová, Amod Kulkarni, Jana Jozefiaková, Zuzana Tkáčová, Tomáš Maľarik, Katarína Kucková, Lea Talpašová, Jakub Víglaský and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Patrícia PetrouškováLaboratory of Biomedical Microbiology and Immunology, The University of Veterinary Medicine and Pharmacy in Košice, Komenského 73, 04181, Košice, Slovakia.
Katarína BhideLaboratory of Biomedical Microbiology and Immunology, The University of Veterinary Medicine and Pharmacy in Košice, Komenského 73, 04181, Košice, Slovakia.
Evelína MochnáčováLaboratory of Biomedical Microbiology and Immunology, The University of Veterinary Medicine and Pharmacy in Košice, Komenského 73, 04181, Košice, Slovakia.
Amod KulkarniLaboratory of Biomedical Microbiology and Immunology, The University of Veterinary Medicine and Pharmacy in Košice, Komenského 73, 04181, Košice, Slovakia.
Jana JozefiakováLaboratory of Biomedical Microbiology and Immunology, The University of Veterinary Medicine and Pharmacy in Košice, Komenského 73, 04181, Košice, Slovakia.
Zuzana TkáčováLaboratory of Biomedical Microbiology and Immunology, The University of Veterinary Medicine and Pharmacy in Košice, Komenského 73, 04181, Košice, Slovakia.
Tomáš MaľarikLaboratory of Biomedical Microbiology and Immunology, The University of Veterinary Medicine and Pharmacy in Košice, Komenského 73, 04181, Košice, Slovakia.
Katarína KuckováLaboratory of Biomedical Microbiology and Immunology, The University of Veterinary Medicine and Pharmacy in Košice, Komenského 73, 04181, Košice, Slovakia.
Lea TalpašováLaboratory of Biomedical Microbiology and Immunology, The University of Veterinary Medicine and Pharmacy in Košice, Komenského 73, 04181, Košice, Slovakia.
Jakub VíglaskýLaboratory of Biomedical Microbiology and Immunology, The University of Veterinary Medicine and Pharmacy in Košice, Komenského 73, 04181, Košice, Slovakia.
Ádám KevélyDepartment of Virus Ecology, Institute of Virology, Biomedical Research Center, Slovak Academy of Sciences, Dúbravská cesta 9, 84505, Bratislava, Slovakia.
Kamila KočiDepartment of Microbiology and Virology, Faculty of Natural Sciences, Comenius University, Ilkovičova 6, 84215, Bratislava, Slovakia.
Eva NovákováDepartment of Virus Ecology, Institute of Virology, Biomedical Research Center, Slovak Academy of Sciences, Dúbravská cesta 9, 84505, Bratislava, Slovakia.
Juraj KočiDepartment of Virus Ecology, Institute of Virology, Biomedical Research Center, Slovak Academy of Sciences, Dúbravská cesta 9, 84505, Bratislava, Slovakia. juraj.koci@savba.sk.ORCID http://orcid.org/0000-0002-5560-806X
Mangesh BhideLaboratory of Biomedical Microbiology and Immunology, The University of Veterinary Medicine and Pharmacy in Košice, Komenského 73, 04181, Košice, Slovakia. bhidemangesh@gmail.com.

Funding

Agentúra na Podporu Výskumu a Vývoja APVV-22-0084Agentúra na Podporu Výskumu a Vývoja APVV-23-0348EuroNanoMed III EURONANOMED2021-105Vedecká Grantová Agentúra MŠVVaŠ SR a SAV VEGA1/0348/22Vedecká Grantová Agentúra MŠVVaŠ SR a SAV VEGA1/0381/23
6 · The paper itself

Abstract

Infection caused by tick-borne encephalitis virus (TBEV) often manifests with meningitis or encephalitis. Domain III (DIII) of the envelope (E) glycoprotein on the TBEV surface facilitates virion attachment to the cell receptor and initiates cell entry. As a result, this research focused on the DIII to develop antiviral molecules that could prevent cell entry. We first identified two receptor-binding sites (RBS,

Indexed as

Antiviral AgentsEncephalitis Viruses, Tick-BornePeptidesViral Envelope ProteinsBinding SitesEncephalitis, Tick-BorneEndothelial CellsHumansPeptide LibraryProtein BindingVirus InternalizationAntiviral AgentsPeptide LibraryPeptidesViral Envelope ProteinsBlocking peptidesCombinatorial phage libraryDomain IIIhBMECsPhage displayPRNTTick-borne encephalitis virusVirus neutralization

Identifiers

PMID40181101
PMCPMC11968884

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.